We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect TransMedics (TMDX - Free Report) to post quarterly loss of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 37.5%. Revenues are expected to be $83.32 million, up 100.5% from the year-ago quarter.
The current level reflects an upward revision of 32.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific TransMedics metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Net revenue by OCS product- OCS Liver net revenue' to reach $56.10 million. The estimate suggests a change of +142.7% year over year.
Analysts predict that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $21.78 million. The estimate indicates a change of +30% from the prior-year quarter.
It is projected by analysts that the 'Geographic Revenues- United States' will reach $77.62 million. The estimate points to a change of +107% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenues- All other countries' of $3.96 million. The estimate indicates a year-over-year change of -2.2%.
TransMedics shares have witnessed a change of +20.7% in the past month, in contrast to the Zacks S&P 500 composite's -3.2% move. With a Zacks Rank #1 (Strong Buy), TMDX is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts expect TransMedics (TMDX - Free Report) to post quarterly loss of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 37.5%. Revenues are expected to be $83.32 million, up 100.5% from the year-ago quarter.
The current level reflects an upward revision of 32.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific TransMedics metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Net revenue by OCS product- OCS Liver net revenue' to reach $56.10 million. The estimate suggests a change of +142.7% year over year.
Analysts predict that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $21.78 million. The estimate indicates a change of +30% from the prior-year quarter.
It is projected by analysts that the 'Geographic Revenues- United States' will reach $77.62 million. The estimate points to a change of +107% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenues- All other countries' of $3.96 million. The estimate indicates a year-over-year change of -2.2%.
View all Key Company Metrics for TransMedics here>>>
TransMedics shares have witnessed a change of +20.7% in the past month, in contrast to the Zacks S&P 500 composite's -3.2% move. With a Zacks Rank #1 (Strong Buy), TMDX is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>